Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®

Data to be shared during an ObesityWeek press conference includes four of seven data presentations supporting CONTRAVE and its utility in helping people lose weight BRENTWOOD, Tenn., Oct. 28, 2025 /PRNewswire/ -- Currax Pharmaceuticals LLC ("Currax"), a pharmaceutical company that...